Ma Xiaoqing, Xu Zhongyang, Ding Shaofeng, Yi Guangkun, Wang Qian
Department of Endocrinology, Jining No. 1 People's Hospital, Jining, Shandong 272000, P.R. China.
Department of Spine Surgery, Jining No. 1 People's Hospital, Jining, Shandong 272000, P.R. China.
Exp Ther Med. 2018 Jan;15(1):182-190. doi: 10.3892/etm.2017.5381. Epub 2017 Oct 27.
Alendronate is commonly used for the treatment of postmenopausal osteoporosis; however, the underlying pathological molecular mechanisms of its action remain unclear. In the present study, the alendronate-treated signaling pathway in bone metabolism in rats with ovariectomy induced by osteoporosis was investigated. Rats with osteoporosis were orally administered alendronate or phosphate-buffered saline (control). In addition, the interferon-β (IFN-β)/signal transducer and activator of transcription 1 (STAT1) signaling pathway was investigated in osteoblasts following treatment with alendronate and . During the differentiation period, IFN-β (100 ng/ml) was used to treat the osteoblast cells, and the activity, viability and bone metabolism-associated gene expression levels (STAT1, p-STAT1, Fra1, TRAF6 and SOCS1) were analyzed in osteoblast cells. Histopathological changes were used to evaluate osteoblasts, osteoclasts, inflammatory phase of bone healing and osteonecrotic areas. The results demonstrated that alendronate significantly inhibited the activity of osteoporotic osteoclasts by stimulating expression of IFN-β, as well as markedly improved the viability and activity of osteoblasts compared with the control group. In addition, alendronate increased the expression and phosphorylation levels of STAT1 in osteoclasts, enhanced osteoblast differentiation, upregulated the expression levels of alkaline phosphatase and osteocalcin, and increased the expression of osteoblast differentiation-associated genes (osteocalcin, osterix and Runx2). Inhibition of IFN-β expression canceled the benefits of alendronate-mediated osteoblast differentiation. Notably, alendronate enhanced bone formation in rats with osteoporosis induced by ovariectomy. In conclusion, these findings suggest that alendronate can regulate osteoblast differentiation and bone formation in rats with osteoporosis induced by ovariectomy through upregulation of IFN-β/STAT1 signaling pathway.
阿仑膦酸钠常用于治疗绝经后骨质疏松症;然而,其作用的潜在病理分子机制仍不清楚。在本研究中,研究了阿仑膦酸钠处理的去卵巢诱导骨质疏松大鼠骨代谢中的信号通路。骨质疏松大鼠口服阿仑膦酸钠或磷酸盐缓冲盐水(对照组)。此外,在用阿仑膦酸钠处理后的成骨细胞中研究了干扰素-β(IFN-β)/信号转导和转录激活因子1(STAT1)信号通路。在分化期,用IFN-β(100 ng/ml)处理成骨细胞,并分析成骨细胞中的活性、活力以及与骨代谢相关的基因表达水平(STAT1、p-STAT1、Fra1、TRAF6和SOCS1)。用组织病理学变化评估成骨细胞、破骨细胞、骨愈合的炎症期和骨坏死区域。结果表明,与对照组相比,阿仑膦酸钠通过刺激IFN-β的表达显著抑制骨质疏松破骨细胞的活性,并显著提高成骨细胞的活力和活性。此外,阿仑膦酸钠增加破骨细胞中STAT1的表达和磷酸化水平,增强成骨细胞分化,上调碱性磷酸酶和骨钙素的表达水平,并增加成骨细胞分化相关基因(骨钙素、osterix和Runx2)的表达。抑制IFN-β表达消除了阿仑膦酸钠介导的成骨细胞分化的益处。值得注意的是,阿仑膦酸钠增强了去卵巢诱导骨质疏松大鼠的骨形成。总之,这些发现表明阿仑膦酸钠可通过上调IFN-β/STAT1信号通路调节去卵巢诱导骨质疏松大鼠的成骨细胞分化和骨形成。